CN108699161B - 多发性骨髓瘤中m-蛋白应答的临床评估 - Google Patents

多发性骨髓瘤中m-蛋白应答的临床评估 Download PDF

Info

Publication number
CN108699161B
CN108699161B CN201780014944.6A CN201780014944A CN108699161B CN 108699161 B CN108699161 B CN 108699161B CN 201780014944 A CN201780014944 A CN 201780014944A CN 108699161 B CN108699161 B CN 108699161B
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
ser
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780014944.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108699161A (zh
Inventor
S·哈特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Morphosys AG
Original Assignee
Morphosys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys AG filed Critical Morphosys AG
Publication of CN108699161A publication Critical patent/CN108699161A/zh
Application granted granted Critical
Publication of CN108699161B publication Critical patent/CN108699161B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ecology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Electrochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
CN201780014944.6A 2016-03-04 2017-03-03 多发性骨髓瘤中m-蛋白应答的临床评估 Active CN108699161B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16158714 2016-03-04
EP16158714.2 2016-03-04
PCT/EP2017/055011 WO2017149122A1 (en) 2016-03-04 2017-03-03 Clinical assessment of m-protein response in multiple myeloma

Publications (2)

Publication Number Publication Date
CN108699161A CN108699161A (zh) 2018-10-23
CN108699161B true CN108699161B (zh) 2022-06-03

Family

ID=55745535

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780014944.6A Active CN108699161B (zh) 2016-03-04 2017-03-03 多发性骨髓瘤中m-蛋白应答的临床评估

Country Status (9)

Country Link
US (3) US11618789B2 (enExample)
EP (1) EP3423498A1 (enExample)
JP (4) JP7362250B2 (enExample)
KR (1) KR102427948B1 (enExample)
CN (1) CN108699161B (enExample)
AU (2) AU2017226960B2 (enExample)
IL (2) IL260750B2 (enExample)
SG (1) SG11201806214RA (enExample)
WO (1) WO2017149122A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019209730A1 (en) 2018-04-24 2019-10-31 Helena Laboratories Corporation Removal of interfering factors from serum protein electrophoresis profiles
CA3111651A1 (en) 2018-09-11 2020-03-19 Jiangsu Hengrui Medicine Co., Ltd. Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
SG11202107319PA (en) 2019-03-15 2021-08-30 Morphosys Ag Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
WO2023094696A1 (en) * 2021-11-29 2023-06-01 Morphosys Ag Methods for reducing anti-cd38 mab drug interference in serological assays

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3912610A (en) * 1974-07-23 1975-10-14 Icl Scient Method for electroquantitative determination of proteins
US4102990A (en) * 1977-12-05 1978-07-25 General Electric Company Electrophoretic assay for antigen-antibody reaction based on particle-particle coupling
US4661586A (en) 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4578350A (en) * 1983-09-23 1986-03-25 Syntex (U.S.A.) Inc. Immunoassays employing protected labels
US6936464B1 (en) * 1992-10-02 2005-08-30 Cancer Research Technology Limited Immune responses to fusion proteins
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2329940A1 (en) 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US7348139B1 (en) * 2001-04-13 2008-03-25 The Johns Hopkins University School Of Medicine SOCS-1 gene methylation in cancer
US6902669B2 (en) 2002-09-13 2005-06-07 Fleetguard, Inc. Filter cartridge with floating seal
EP1544215A1 (en) 2003-12-17 2005-06-22 Institut National De La Sante Et De La Recherche Medicale (Inserm) Human anti-idiotypic antibody fragments that mimic HER-2/neu
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
WO2006125640A2 (en) 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
MXPA06008700A (es) * 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
KR101289537B1 (ko) 2005-02-15 2013-07-31 듀크 유니버시티 항-ｃｄ19 항체 및 종양학에서 이의 용도
EA037929B1 (ru) * 2005-03-23 2021-06-08 Генмаб А/С Антитела к cd38 человека и их применение
HUE035250T2 (hu) 2005-10-12 2018-05-02 Morphosys Ag Humán CD38-ra specifikus teljesen humán HuCAL GOLD-eredetû terápiás ellenanyagok létrehozása és profilozása
EP2046367A4 (en) * 2006-06-07 2009-11-11 Human Genome Sciences Inc ALBUM INFUSION PROTEINS
US20080066739A1 (en) * 2006-09-20 2008-03-20 Lemahieu Edward Methods and systems of delivering medication via inhalation
US9382327B2 (en) * 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2010002911A2 (en) * 2008-06-30 2010-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods and materials for monitoring myeloma using quantitative mass spetrometry
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
PL2621531T3 (pl) 2010-09-27 2017-07-31 Morphosys Ag Przeciwciało anty-CD38 i lenalidomid lub bortezomib do leczenia szpiczaka mnogiego i NHL
CA2811747A1 (en) 2010-09-30 2012-04-05 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her3 antibodies
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
ES2661575T3 (es) 2012-03-30 2018-04-02 The Board Of Regents Of The University Of Oklahoma Producción de polímeros de heparosano de peso molecular alto y métodos de producción y uso de los mismos
AU2013322806C1 (en) 2012-09-25 2018-03-08 Morphosys Ag Combinations and uses thereof
CA2909952C (en) 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
CA2927099A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
PT3105317T (pt) * 2014-02-14 2019-02-27 Cellectis Células para imunoterapia manipuladas para atuar sobre antigénios presentes tanto em células imunitárias como em células patológicas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab

Also Published As

Publication number Publication date
IL260750A (enExample) 2018-09-20
EP3423498A1 (en) 2019-01-09
US20230203189A1 (en) 2023-06-29
JP7362250B2 (ja) 2023-10-17
IL305540A (en) 2023-10-01
IL260750B2 (en) 2024-02-01
AU2017226960B2 (en) 2024-03-21
KR102427948B1 (ko) 2022-08-02
SG11201806214RA (en) 2018-08-30
JP2022058881A (ja) 2022-04-12
US11618789B2 (en) 2023-04-04
KR20180118151A (ko) 2018-10-30
AU2017226960A1 (en) 2018-08-09
US20190077875A1 (en) 2019-03-14
IL260750B1 (en) 2023-10-01
US20240392034A1 (en) 2024-11-28
CN108699161A (zh) 2018-10-23
JP7331168B2 (ja) 2023-08-22
CA3016098A1 (en) 2017-09-08
JP2023157927A (ja) 2023-10-26
AU2024201503A1 (en) 2024-03-28
JP7557023B2 (ja) 2024-09-26
WO2017149122A1 (en) 2017-09-08
IL305540B1 (en) 2024-05-01
JP2019513346A (ja) 2019-05-30
IL305540B2 (en) 2024-09-01
JP2024169455A (ja) 2024-12-05

Similar Documents

Publication Publication Date Title
JP7557023B2 (ja) 多発性骨髄腫におけるｍタンパク質反応の臨床評価
WO2023025315A1 (zh) 抗b7-h3抗体、其制备方法及用途
CN109627338B (zh) 一种新型抗人pd-l1抗体及其应用
CN117343182B (zh) 抗人tigit抗体或其功能性片段及其应用
ES2530265T3 (es) Ensayos de potencia de unión de una sustancia medicamentosa de anticuerpo a un receptor FC
CN109336973A (zh) 抗转铁蛋白抗体及其用途
CN120441707B (zh) 结合特瑞普利单抗的抗体及其用途
HK1261804A1 (en) Clinical assessment of m-protein response in multiple myeloma
HK1261804B (en) Clinical assessment of m-protein response in multiple myeloma
TW201840588A (zh) 抗ｇｐｒ２０抗體
CN120424221B (zh) 靶向德曲妥珠单抗的抗体及其用途
CN116836291B (zh) 抗cd47-cldn18.2双特异性抗体的抗独特型抗体及其制备方法和应用
CA3016098C (en) Clinical assessment of m-protein response in multiple myeloma
CN112724253B (zh) 抗人穹窿体蛋白的抗体及其应用
KR102688094B1 (ko) Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
WO2025218662A1 (zh) 抗成纤维细胞生长因子受体2b的抗体及其用途
CN120923624A (zh) 可结合人cd137单克隆抗体或其功能性片段及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261804

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant